Study quality of life after SBRT for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies how well people do—especially their quality of life—after SBRT radiation for primary kidney cancer that can’t be removed with surgery. It may help doctors understand which patients benefit most and what side effects to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your kidney cancer is newly diagnosed, or it grew during surveillance, or it came back after another local treatment.
- The main tumor is larger than 3 cm (or it is a recurrent tumor after prior local treatment).
- A specialist believes surgery is not possible for you medically, or you choose not to have surgery.
- Your overall health function is fairly good (ECOG 0–2).
- You can give informed consent and understand English (or use a translator).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise type of radiation called stereotactic body proton therapy for people with kidney cancer who cannot have surgery or other local treatments. It aims to see if this focused radiation can control the tumor with fewer side effects.
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
This study tests whether a precise, high-dose radiation treatment (SABR) can safely control kidney cancer that has spread to a few spots in the body. It may be an option if your cancer is progressing during treatment and your spots can be safely targeted with radiation.
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
This trial tests a precise type of radiation therapy for small, early-stage kidney tumors that cannot be surgically removed or are at high risk for surgery. It aims to offer an alternative treatment with fewer side effects.
This study follows people with liver cancer (hepatocellular carcinoma) to see how their quality of life changes after a focused form of radiation called stereotactic ablative radiation therapy. It does not appear to test a new drug—rather, it measures patient-reported well-being after treatment.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.